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Abstract
Purpose—To determine caregiver perceptions about population screening for fragile X and
examine factors potentially associated with support for screening.
Method—We asked 1,099 caregivers of a child with fragile X syndrome or a fragile X carrier to
rate whether free, voluntary screening should be offered preconception, prenatally, neonatally, or
when problems occur. Caregivers chose a preferred time for screening, reported whether screening
would affect parent–child bonding, indicated preferences for carrier detection, and gave reasons
for their choices.
Results—Caregivers endorsed all forms of screening, but prenatal screening was less strongly
endorsed than preconception or postnatal screening. Most (79%) preferred preconception carrier
testing, allowing more options when making reproductive decisions. Most thought that screening
should also disclose carrier status and believed a positive screen would not negatively affect
parent–child bonding. Maternal education, caregiver depression, family impact, and severity of
disability were not associated with screening opinions, but parents who only had carrier children
were less likely to endorse prenatal screening.
Conclusion—Caregivers of children with fragile X widely endorse screening. But because
different parents will make different choices, screening may need to be offered at multiple times
with careful consideration of consent and informed decision making.
Introduction
The possibility of population screening for fragile X syndrome (FXS), the most common
cause of inherited intellectual disability, demonstrates the complexities inherent in policy
decisions.1 FXS results from an expansion of the FMR1 gene to more than 200 CGG
repeats, resulting in a reduction or elimination of FMRP, a protein necessary for normal
brain development. Currently, DNA testing is required to detect FXS (c.f., Tassone et al.2),
which means that any screening that detects FMR1 gene expansions could also identify
premutation carriers (55 to 200 CGG repeats). In this paper, we use FXS to refer to
individuals who have the syndrome and FX to refer to all FMR1 gene expansions, including
premutation carriers. Female carriers can have children with FXS; female carriers are at
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increased risk for ovarian insufficiency and males (and to a lesser extent females) for fragile
X tremor-ataxia syndrome (FXTAS), both adult-onset conditions.3
Symptoms of FXS (developmental delay, sensory issues, behavior or attention problems) are
not evident at birth, gradually appearing as developmental delays during the first 2 years of
life. Because of the lack of symptom specificity and delays in genetic testing, the average
age of diagnosis is 35-37 months.4 Population screening for FX is possible; could occur at
various times with varying benefits and costs; and could include carrier screening, screening
for affected individuals, or both. Because FX is inherited from carrier parents, preconception
screening could enable reproductive decisions prior to pregnancy.5 Prenatal screening could
be offered to determine maternal carrier status or whether the fetus has FX.6, 7, 8 Newborn
screening could determine whether a neonate has FX.9 In the early childhood period,
screening could be offered selectively to high-risk populations10 or at the first sign of
developmental problems. Each option has its own merits and limitations11. The opinions of
various stakeholders—professionals, the general public, parents—should inform decisions
about when and how to offer screening.
Professional organizations constitute one important stakeholder perspective, but no one
organization speaks for all forms of screening. The American College of Medical Genetics12
and a joint statement by the Child Neurology Society and the American Academy of
Neurology13 recommend that any child with unexplained delays be tested for FXS. The
American Academy of Pediatrics has no formal position on FX testing, but the Committee
on Genetics urged pediatricians to consult with clinical geneticists to reduce the time
between presenting signs and a genetic diagnosis.14 The American College of Obstetricians
and Gynecologists15 recommends offering prenatal testing to any known FX carriers; FXS
testing for any child with developmental delay, autism, or autistic behavior; and carrier
testing to women over 40 years of age with ovarian failure or an elevated follicle-stimulating
hormone level. The National Society of Genetic Counselors16 and a multicenter working
group of genetic counselors17 suggest testing possibly affected individuals followed by
cascade testing of extended family members once a target individual has been confirmed.
Practicing professionals may or may not agree with an organization's policy statement. A
2005 survey of pediatricians found that only about one-third would support newborn or
infant population screening for FXS.18 However, in a 2009 survey, 78% of pediatricians
believed that newborn screening for FXS would be beneficial for children and families, and
58% believed that parents should be offered FXS screening for their infant as part of well-
child care.19 A 2006 survey of genetic counselors reported that 20% supported newborn
screening, 36% supported population screening later in infancy, and 73% supported testing
of high-risk infants.20 In a 2009 survey of physician geneticists and genetic counselors,
about 60% supported newborn screening for FXS but were less supportive if screening
identified carriers.21 When asked to choose the best screening model, 72% endorsed either
preconception universal screening (29%) or high-risk population screening (43%).
Assessing general public opinion is hampered by the public's general lack of awareness of
genetics and screening, and lack of knowledge about conditions such as FXS or the
difference between carrier and affected status.22 We are not aware of any surveys assessing
population opinions about FX screening. However, one indication can be found in uptake
rates when parents are offered screening. A recent review found 10 studies in which FX
screening was offered to pregnant or preconception women of reproductive age.23
Considerable variability in acceptance rates was reported, ranging from 8% to 92%. Because
the studies were conducted in different countries using different protocols for screening at
different times, it is impossible to make a general statement about the acceptability of FX
screening to the “general public,” although most studies report that once women understand
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the information that could be gained, most support voluntary screening options. Two studies
have reported acceptance rates in FX newborn screening. A pilot study offering screening
for FXS to mothers of 1,844 male infants born in South Carolina reported a 79% acceptance
rate.24 A recent study offering screening for FX (premutation and full mutation) to parents
of 2,137 male and female newborns in North Carolina reported that 63% elected to
participate.25
A final perspective is the opinions of families who have a child with FXS. Patient advocacy
groups historically have exerted a strong influence on screening programs, but even families
who have experienced a medical condition in one of their children vary in their opinions
about screening.26 Relatively little is known about the opinions of parents of children with
FXS, limited to a single study.27 Of 442 mothers and fathers from 290 families, most
supported voluntary FX screening at all possible times (preconception, prenatal, newborn,
high-risk screening); when forced to choose only one option, most (80%) chose “before a
woman gets pregnant.” Most parents felt that screening would not disrupt the bond between
parent and child, and most endorsed disclosure of carrier status for both prenatal (87%) and
newborn (94%) screening. Demographic variables (gender, education, income) were not
associated with screening opinions, but religiosity was moderately related to prenatal
screening.
The present study replicates and extends the 2003 Skinner et al. study, using a much larger
sample of families (1,099) who have at least one child with FX (families could have a child
with FXS or only premutation carriers) and examining whether a broader range of variables
(respondent education level, age, history of depression, family configuration, and perceived
impact of FX on the family) was associated with screening opinions. We hypothesized that
families who had experienced more negative ramifications of FX (depression, more than one
affected child, more severely affected children, and cumulative negative family impact)
would be more likely to support a variety of screening options.
Methods and Materials
The data reported were collected as part of a U.S. FX survey.28 Parents or other caregivers
provided information about a range of topics, including age of diagnosis, co-occurring
conditions, school services, adult life, and family adaptation. The opinion questions
regarding population screening are the focus of this paper.
Subjects
The sample was a large but non-representative group of parents or other caregivers from
each of 1,099 families of children with FX who responded to all screening items in the
national survey. Most respondents were mothers (87%); the remainder were fathers (9%),
grandparents, or others (4%). Most (92%) were Caucasian, 4% Hispanic, 2% African
American, and 2% from other races or ethnicities. The group was better educated and more
affluent than the U.S. population. More than half (58%) had a college degree or higher, 27%
had some college, and 15% had a high school degree or less; 56% reported a household
income of greater than $75,000 per year. Respondents ranged in age from 16 to 89 years
(M= 47).
Procedures and Instrumentation
Information about the survey was circulated by three FX foundations, researchers, and
clinicians. Families completed the survey on the Internet (76%) or by calling a toll-free
number (24%). The survey consisted primarily of closed-ended questions about each child
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as well as the family as a whole. A complete description of the survey procedures and major
findings are provided in Bailey, Raspa, and Olmsted.28
One section addressed parent opinions about FX population screening. We used the same
questions from our earlier article27 for comparative purposes. On a scale from 1 (strongly
disagree) to 5 (strongly agree), caregivers indicated whether they agreed that free and
voluntary testing should be offered: (a) to identify if a woman is a carrier of FX before
pregnancy (preconception carrier screening), (b) to identify if a woman is a carrier during
pregnancy (prenatal maternal screening), (c) to identify if a baby has FX before birth
(prenatal fetal screening), (d) to identify if a newborn has FX shortly after birth (newborn
screening), and (e) to identify a child with developmental or behavioral problems (problem-
based screening). Caregivers were then asked, “If you had to choose only one of the
following statements, which would it be?” followed by the above five options plus “genetic
testing for FX should not be offered at any time,” “other (please specify),” and “don't
know.” Two questions asked how prenatal or newborn screening might affect bonding
between caregiver and child (more difficult, no effect, easier, don't know). Finally, parents
were asked, “If you or your spouse/partner had a genetic test during pregnancy that showed
that your baby was not affected, but is a carrier of FX, would you want to be informed of
this at that time?” (yes, no, don't know). A similar question was asked about newborn carrier
identification. For several questions (best time for screening, bonding, knowing carrier
status), an open-ended section asked parents to explain their choice.
Data Analysis
SAS (Version 9, Cary, NC) and SUDAAN® (Research Triangle Institute, Research Triangle
Park, NC) were used for all quantitative analyses. Percentages were calculated for most
variables, including demographic information and item response distribution. Logistic
regression models were used to determine whether parent opinions were associated with
four caregiver variables and two child variables. Of the 1,099 families, 1,045 were included
in the logistic regression models because they had no missing values. Content analysis was
conducted for all open-ended responses.
Family predictors—Two caregiver variables (respondent education level, respondent age)
were incorporated to test the assumption that respondents with more education or with
younger children would be more supportive of screening. Two additional caregiver variables
(respondent history of depression, perceived impact of FX on the family) tested the
assumption that families more negatively affected by FX would be more supportive of
screening. Respondents reported whether they had ever been diagnosed or treated for
depression, and if so, how many times. Respondents were assigned to one of three groups:
never (64%), once (15%), or two or more times (21%). With regard to family impact,
respondents were assigned to one of these groups depending on their response to the
question: “Overall, thinking about the impact of FX on your family, has it been mostly
positive (18%), somewhat positive (35%), somewhat negative (33%), or mostly negative
(14%)?”
Child predictor variables—Two explanatory variables combined information on the
mutation status and level of severity of children with FX. Our assumption was that more
children with FX and the cumulative severity of child impact would be associated with
greater endorsement of screening. We created four mutually exclusive groups (family
configuration) based on the number and genetic status of the family's children: Group 1: one
or more children with the premutation FX and no children with FXS (N = 67, 6%); Group 2:
one or more females with FXS and no males with FXS (N = 111, 11%); Group 3: only one
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male with FXS, but possibly female children with FXS (N = 727, 70%); and Group 4: more
than one male with FXS and possibly female children with FXS (N = 140, 13%).
A severity score was calculated as the sum of total conditions for all affected children.
Following the procedures reported by Ouyang, Grosse, Raspa, and Bailey,29 the total
conditions score for each child ranged from 0 to 9, reflecting the number of “yes” answers to
questions about diagnosis or treatment for developmental delay or eight co-occurring
conditions (attention, hyperactivity, aggression, self-injury, autism, seizures, anxiety,
depression). This variable reflects the total number of co-occurring conditions in the family.
For example, in a family with two affected children with total co-occurring conditions
scores of 3 and 6, respectively, the cumulative severity score would be 9. Across the sample,
the severity score ranged from 0 to 31, with a median of 5, and a mean of 5.75 (SD = 3.72).
A logistic regression model was run for each screening option (preconception carrier,
prenatal maternal carrier, prenatal fetus, newborn, or problem-based screening). Each model
included respondent education and age, history of depression, perceived family impact,
family configuration, and the cumulative severity score. To simplify the analysis, we
converted the ordinal scales ranging from 1 (strongly disagree) to 5 (strongly agree) to 0
(undecided/disagree/strongly disagree) or 1 (agree/strongly agree).
Results
Opinions about Screening
Caregiver opinions are displayed in Figure 1. Most either agreed or strongly agreed that free,
voluntary screening should be offered at all times, but with substantial variability:
preconception carrier screening (83%), prenatal maternal carrier screening (68%), prenatal
fetal screening (61%), newborn screening (84%), and problem-based screening (89%). A
comparison of the combined prenatal screening options with the combined preconception or
postnatal screening options indicates that parents were significantly less likely to endorse
prenatal screening of either mother or fetus than preconception, newborn, or problem-based
screening, χ2(1, N = 1,099) = 338.3, p < .0001. Prenatal screening is the option for which
parents were more likely to indicate “uncertain,” likely reflecting the controversies and
difficult decisions associated with prenatal testing.
Forced Choice Selection
When forced to select one option, about three-fourths (76%) preferred preconception carrier
screening. Of these, 283 caregivers provided a reason; the vast majority (89%) said that
preconception screening would inform reproductive decisions. Most comments indicated
that preconception diagnosis would provide more reproductive control and options (“If this
information is known prior to conception, a woman can make an informed decision about
having a child.” “I feel testing before becoming pregnant offers the greatest number of
choices.”) Other comments indicate that the most likely benefit would be to avoid the risk of
having a child who could have FXS (“I love my child dearly, but I would have liked to have
the option to not have a child with this disability.”) and, for some, to pursue adoption or
assisted reproductive technology (“If I had known, I wouldn't have gotten pregnant with my
own genes.”).
Approximately 9% preferred newborn screening. Almost all of the 40 comments stated that
newborn screening would make it possible to provide special education or therapies as early
as possible (“If you know that the child has fragile X shortly after birth you could get better
education for the baby instead of waiting until 2 years old.” “The earlier the intervention for
that child, the better the outcome for that child's future”). A few parents also noted that
newborn screening would have prevented the frustrations they experienced not knowing
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whether the child had a problem or its cause (“Had he been tested I would have known from
the get go and had closure—it's the not knowing what is wrong with your newborn that
drives you crazy.”). For both preconception and newborn screening, some parents saw
screening at these times as precluding an abortion that might occur if the diagnosis was
during pregnancy.
About 7% preferred screening once developmental or behavioral problems occur. The 31
comments reflected the predominant theme that diagnosis should only happen when a
problem becomes evident (“There is already so much for a mother to learn and do with a
newborn. If there are no signs or symptoms at birth, then why throw it at them then when
4-6 months later would be fine.”).
Only 3% endorsed prenatal screening as the best time. Comments indicated that FX
screening should be offered concurrently with other prenatal tests for abnormalities like
Down syndrome. Only one woman said she would have used this information for pregnancy
termination. Other parents wrote that prenatal testing would inform them of the
circumstances they would face but did not elaborate. Over a third indicated that information
during the prenatal period would help prepare for the future (“So parents can prepare for
what lies ahead.” “Having a diagnosis before birth allows for therapies to be lined up to
begin as needed as soon as possible.”). Only 1.4% felt that screening should not be offered
at any time, and 3.7% either did not know or wrote extraneous comments.
Effects on Bonding
In general, caregivers did not believe that a positive test for FX would affect bonding. A
majority reported that a positive test would have no effect, whether screening during
pregnancy (58%) or shortly after birth (63%). Over 500 comments were submitted by the
caregivers who said that screening would have no effect on bonding. Virtually all of them
said that they would love and accept their child regardless of genetic status (“When you
bring a child into the world you are going to bond or not no matter what ‘condition’ it may
have.” “I would have fallen in love with him the minute I first held him no matter what.”).
Some families thought that prenatal (9%) or newborn (13%) screening would make bonding
easier. Their written comments suggested that screening would explain abnormalities in
development, providing more understanding or preventing feelings of guilt or blame (“I
blamed myself for his lack of showing affection early on, his learning difficulties.” “We
were frustrated with not knowing what was different about him. This had a negative effect
on bonding with him—if we knew what was up, there would have been less frustration.”).
A minority of families felt that it might make bonding more difficult (11% prenatal
screening, 8% newborn screening). These families wrote that knowing might have made
them grieve or worry, and although they loved their child, they were concerned that these
feelings could have had a negative impact. They noted that knowing would have affected the
positive experience of pregnancy, and their views of and early interactions with the child (“I
would have been so scared. I think I would have cried and worried my whole pregnancy and
not enjoyed it like I did.” “Most people would expect great things from their offspring;
knowing there is a problem right away would decrease my ability to encourage interaction
and development.”).
But many caregivers acknowledged that they did not really know what the effect of prenatal
(22%) or newborn (15%) screening might be. Comments reflected ambivalence about
wanting to know but not wanting to worry about the negative effects knowing could bring
(“I think I would still love and bond with the baby, but the trepidation of the unknown
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would interfere with the joy of the pregnancy.” “I want to believe that it would make no
difference, and I don't think it would, but in trying to be honest, I don't really know.”).
Carrier Testing
Most parents indicated that they would like to be informed about carrier status, either with
prenatal (86%) or newborn (92%) screening. The major reasons given in the 700 comments
included the desire to have any and all relevant health information about their child, the
feeling that they have a right to know this information, and the potential utility of
information in preparing their child for the future (“If it was known, I'd want to know. I
wouldn't want someone keeping the information from me, and I would probably tell my
child early so they'd grow up knowing it, in an age-appropriate manner.”). The parents who
did not want to know this information or were uncertain mostly questioned whether the
information had any real utility and whether knowing would cause unnecessary worry.
Modeling
Despite the considerable variability in the predictor variables, only one (family
configuration) was associated with screening opinions. Families who only had children with
the premutation (and no children with the full mutation) were significantly less likely to
endorse fetal prenatal screening than families who had a male child with the full mutation
(OR = .48, p < .01). Interestingly, families who had two or more male children with the full
mutation tended to be less supportive of screening than families who only had female
children with the full mutation or families with only one male child with FXS, although this
difference only reached significance for prenatal maternal carrier screening (OR = .61, p < .
03).
Discussion
Botkin30 recently wrote a commentary entitled: “Newborn Screening for Fragile X
Syndrome: Do We Really Care What Parents Think?” Since newborn screening historically
has been conducted without parental consent under a public health protocol for conditions
needing prompt treatment, parent opinions about screening are rarely sought. But screening
for FX is a more complicated issue, since no medical treatment is currently available and
carriers would be identified. Furthermore, some individuals with FXS are much more
seriously affected than others, and the consequences for some families are more negative
than for others. How, when, and whether to offer population screening for FX in the absence
of clinical symptoms is a complex set of questions that requires data from multiple
perspectives. Parents and other caregivers of affected children comprise an important
stakeholder group whose opinions about screening need to be known. In this article we used
a sample of more than 1,000 families who had a child with the fragile X premutation or the
full mutation FXS to determine caregiver opinions about various forms of population
screening and to determine whether the severity or magnitude of the impact of FX on the
family had any bearing on parent opinions.
The majority of caregivers supported screening for both the full mutation FXS as well as for
premutation carriers. They endorsed screening at all of the times presented, though ratings of
prenatal testing were significantly lower, reflecting the limited options for doing anything at
that time and perhaps concerns about abortion. This finding is consistent with other research
showing that, for the most part, parents want genetic and health information that has any
bearing on the well-being of their children.31-33 Studies of families of children with other
conditions vary in the extent to which the availability of a known condition-specific
treatment affects parent opinions.34-36 But consistent with most of these studies, many
parents of children with FXS felt that earlier identification would enable access to early
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intervention and therapy services, even though those services are not FXS specific and their
efficacy with FXS has not been demonstrated. This finding suggests that parents generally
have a broad view of what constitutes treatment and treatability.37,38 However, some parents
reflected, as shown in other studies,39 that they were ambivalent about knowing, because
screening might mean they would not have the children they have now.
When forced to choose one time for screening, the majority (76%) of caregivers endorsed
preconception screening. The common theme among virtually all of the respondents was the
desire to know ahead of time so that they could “have a choice” about whether to risk having
a child with FXS. The strong preference for preconception screening found in this study,
however, contrasts with the 20% acceptance rate in the only pilot study reporting uptake
rates for nonpregnant women.5 Many factors likely influence acceptance of preconception
carrier testing, including maternal age, cost of the test, family history of disability or
developmental problems, perception of risk, and intent to have a child in the near future.
Voluntary population-based preconception carrier testing, while strongly endorsed by
parents of affected children, will likely be challenging to implement in a way that achieves
any broad-based public health goals, especially given the fact that nearly 50% of U.S.
pregnancies and more than 40% of pregnancies worldwide are unintended.40,41
We had hypothesized that families more affected by FX (higher rate of caregiver depression,
more severely affected children, perceived negative family impact) would more strongly
endorse all forms of screening. Surprisingly, none of these variables were associated with
opinions about screening, nor was caregiver age or education. The only variable associated
with screening opinions was family configuration; families who only had premutation
children were significantly less likely to endorse prenatal screening, although the magnitude
of difference was relatively small. This finding suggests that families who only have carrier
children may feel less urgency about the need to know, even though most still endorsed all
forms of screening.
Although this is by far the largest study of parent opinions about FX screening, the survey
sample was not representative of families with children with FX in the U.S. population; thus,
the findings must be interpreted accordingly. Very few families from ethnic minority groups
participated and the sample reported higher levels of income than the U.S. population.
Because family income and maternal education are highly correlated and we had more
variability in maternal education, we examined the association between maternal education
and opinions about screening but not for minority status because cell sizes were small. The
study of necessity is based on caregiver report. Although opinion data are useful, some
outcomes (e.g., effects of screening on parent–child bonding) can only be evaluated
definitely in the context of a prospective longitudinal study. We also relied on caregivers'
reports of other variables such as co-occurring conditions and genetic status of their
children. Although parents and other caregivers can provide important information about the
nature and consequences of a condition and the symptoms that are of most concern to them,
we did not have diagnostic confirmation of these study variables. Finally, these findings may
not pertain to opinions of families in countries other than the United States.
Despite these limitations, this study provides a definitive view of caregiver perspectives on
population screening for FX in the U.S. Consistent with findings from our earlier study,27
parents who have experienced raising a child with FX strongly endorse all forms of
population screening, although they are significantly less likely to endorse prenatal
screening, and when forced to choose, most would prefer preconception carrier testing.
The empirical base for population screening for FX remains scant.23 More systematic
investigations comparing screening options and examining the long-term costs and benefits
Bailey et al. Page 8
Genet Med. Author manuscript; available in PMC 2013 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
of each are needed. These investigations will need to consider the likely variability in
individual preferences for screening and the subsequent need for, and costs associated with,
informed consent and informed decision making at various times for screening. If current
clinical trials of mGluR5 antagonists and GABA agonists addressing the core mechanisms
affected by FXS42,43 show treatment efficacy and studies demonstrate that treatment is safe
and maximally effective when provided early in life, it will be interesting to see whether and
how the dynamic of population screening for FX changes.
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Figure 1.
Percentage of caregivers who agree that free, voluntary genetic testing should be offered at
different times.
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